Results 51 to 60 of about 3,389 (131)

Actividad de una nueva combinación de β-lactámico e inhibidor de β-lactamasas (imipenem/relebactam)

open access: yes, 2019
[spa] Pseudomonas aeruginosa es uno de los patógenos oportunistas con mayor capacidad de desarrollar resistencia a antibióticos, ya sea por mutaciones cromosómicas o por la adquisición de genes de resistencia; lo que conlleva a la necesidad de ...
Orellana Ponce, Rocío Antonela
core  

Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach.

open access: yes, 2020
Imipenem/cilastatin/relebactam is a β-lactam/β-lactamase inhibitor that has been recently FDA approved for complicated intra-abdominal and urinary tract infections under the brand name Recarbrio®.
Paul Fimognari   +8 more
core   +1 more source

In vitro, intracellular and in vivo s ynergy between amoxicillin, imipenem and relebactam against Mycobacterium abscessus

open access: yes
International audienceAbstract Objectives : Mycobacterium abscessus is the most frequent of the rapidly growing mycobacteria responsible for lung infections in patients suffering from cystic fibrosis and COPD.
Bitar, Maria   +4 more
core   +1 more source

Diastereoselective FeCl3·6H2O/NaBH4 Reduction of Oxime Ether for the Synthesis of β‑Lactamase Inhibitor Relebactam

open access: yes, 2019
Relebactam, a potent β-lactamase inhibitor, in combination with Primaxin is an FDA-approved (Recarbrio) treatment for serious and antibiotic-resistant bacterial infections. An efficient synthesis of key chiral piperidine intermediate 1 suitable for large-
Aaron Dumas   +21 more
core   +1 more source

In Vitro Susceptibility to Imipenem/Relebactam and Comparators in a Multicentre Collection of Mycobacterium abscessus Complex Isolates

open access: yes
Background and Objectives: Infections caused by non-tuberculous mycobacteria (NTM), including Mycobacterium abscessus complex (MABc), are increasing globally and are notoriously difficult to treat due to the intrinsic resistance of these bacteria to many
Verónica Gonzalez-Galán   +12 more
core   +1 more source

Additional file 4: of In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa

open access: yes, 2019
Figure S1. Minimum inhibitory concentrations (MIC50/90, expressed in μg/mL) for imipenem (A) and imipenem with 4 μg/mL relebactam (B), mapped onto a dendrogram of P. aeruginosa PDC alleles.
Douglas Wisniewski (2404219)   +13 more
core   +1 more source

Additional file 3: of In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa

open access: yes, 2019
Table S1. P aeruginosa isolate sources. Table S2. Primers used in the construction of P. aeruginosa RND-overexpressing strains. Table S3. Inoculum effect control data. Table S4.
Douglas Wisniewski (2404219)   +13 more
core   +1 more source

AmpC induction by imipenem in Pseudomonas aeruginosa occurs in the absence of OprD and impacts imipenem/relebactam susceptibility

open access: yes
In the United States, carbapenem resistance in Pseudomonas aeruginosa is linked to the regulation of chromosomal resistance determinants, AmpC and OprD.
Nancy D. Hanson, Shawn Freed, Jr
core   +1 more source

Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones

open access: yes
[eng] Objectives: To analyse the dynamics and mechanisms of stepwise resistance development to ceftolozane/tazobactam and imipenem/relebactam in XDR Pseudomonas aeruginosa clinical strains.
Gomis-Font, María A.   +6 more
core   +1 more source

In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa [PDF]

open access: yes, 2019
[eng] Pseudomonas aeruginosa, is a major cause of nosocomial and chronic infections, being considered a paradigm of antimicrobial resistance development.
Gomis Font, Maria Antonia
core  

Home - About - Disclaimer - Privacy